In addition to surgery, radiation therapy, and chemotherapy, targeted therapies against the well-characterized oncogenic driver mutations in lung ADC, such as EGFR, BRAF, KRAS, and ALK fusion, have been widely administered as ADC treatments2. The gene discussed is ALK; the disease is AIDS dementia complex.